comprehensive -WSS

comprehensive

author：entertainment 2025-08-12 05:30:45 - browse：923

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： At JPM 2024, hospital systems pitch financial strength to investors

WSS

How the first Native Hawaiian psychiatrist helped diversify medicine

Health officials lay out plans to cope with respiratory virus season

At JPM 2024, hospital systems pitch financial strength to investors

Trans patients at the end of life deserve respect and dignity

In shift, Texas to cover initial consult for Afghan baby's gene therapy

FDA greenlights medical device to combat bladder issues

hotspot

comprehensive

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Meadows told special counsel he could not recall Trump ever declassifying Mar

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA early review: GLP

Cancer drug shortages should be causing more outrage

Roche's accidental data boosts hopes for anti

Affirmative action in medical school literally saved lives

Kellogg’s is going to war over Mexico’s nutrition label rules

Medicare details structure of new drug price negotiation program

At JPM 2024, hospital systems pitch financial strength to investors

hotspot

Study suggests new cause of Down syndrome: cells linked to aging

Arena BioWorks launches in Cambridge to speed drug discovery

A preacher's new calling: Diversifying neuroscience research

At JPM 2024, hospital systems pitch financial strength to investors

Merck to acquire Harpoon Therapeutics for $680 million

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

leisure time

focus

focus